Cambridge Healthtech Institute’s Second Annual
Immunogenicity Prediction and Mitigation
Risk Factors, Predictive Tools And Immune Tolerance Approaches
Part of the Tenth Annual PEGS: the essential protein engineering summit
May 8-9, 2014| Seaport World Trade Center | Boston, MA
Immunogenicity of therapeutic proteins can render the product ineffective and potentially dangerous. Investigators need to know what causes immunogenicity and how to identify immunogenic features to enable them to design their product accordingly. This track will showcase cutting-edge approaches for the identification of risk factors and for designing non-immunogenic biotherapeutics.
Measures to Control Immunogenicity to Interferon Beta
Florian Deisenhammer, Ph.D., Clinical Department of Neurology, Innsbruck Medical University
Novel Approach to B and T Epitope Removal from Cancer Immunotoxins with No Loss of Activity
Ira Pastan, M.D., NIH Distinguished Investigator, Co-Chief, Laboratory of Molecular Biology, National Cancer Institute, National Institutes of Health
Mathematical Modeling of Immunogenicity for Candidate Selection and Prediction of Effect on Clinical Efficacy
Tim Hickling, Ph.D., Associate Research Fellow, Pharmacokinetics, Dynamics and Metabolism, Pfizer, Inc.
Immunogenicity Prediction Studies with a Recently Terminated Factor VII Analogue Project
Kasper Lamberth, Ph.D., Head, Immunogenicity Prediction & Tolerance, Novo Nordisk A/S
Integrated Application of a Risk Assessment Toolkit for Investigation of an Immunogenic Monoclonal Antibody Therapeutic
Bonnie Rup, Ph.D., Research Fellow, Immunogenicity Sciences Lead, Pfizer, Inc.
Understanding the Immune Response against Erythropoiesis Stimulating Agents that Can Lead to Pure Red Cell Aplasia
Steven J. Swanson, Ph.D., Executive Director, Medical Sciences (Clinical Immunology), Amgen, Inc.
Designing and Engineering a Protein Therapeutic For Topical Treatment of Ocular Surface Inflammatory Disorders to Have Low Immunogenic Potential
Joe Kovalchin, Ph.D., Lead, Pharmacology and Non-Clinical, Eleven Biotherapeutics, Inc.
Advances in Immune Tolerance induction for Replacement Enzymes
Susan Richards, Ph.D., Global Deputy and Head, Clinical Laboratory Science, Genzyme, Inc.
Immune Tolerance Induction in Hemophilia A Mice Treated with Factor VIII Fc Fusion Protein
Sriram Krishnamoorthy, Ph.D., Scientist, Preclinical and Clinical Development (Hemophilia), Biogen Idec, Inc.
Reverse Vaccination via S.C. Route to Mitigate Immunogenicity
Sathy Balu-Iyer, Ph.D., Associate Professor, Pharmaceutical Sciences, SUNY-University at Buffalo
Are Aggregates Really Immunogenic? Relevance of Current in Vitro and In Vivo Test Systems in Understanding Physiological Immune Response to Aggregated Particles
Vibha Jawa, Ph.D., Principal Scientist, Clinical Immunology, Amgen Inc.
Aggregation of Human Recombinant Monoclonal Antibodies Enhances Their Presentation by Dendritic Cells In Vitro
Sebastian Spindeldreher, Ph.D., Head, Biologics Safety and Disposition, Novartis
Biological Impact of Aggregates: Immunogenicity, Biodistribution, In Vivo Response
Vasco Filipe, Ph.D., Research Scientist, ADOCIA